Rare Cancer Day: Dxcover's PANAROMIC platform for early detection

Dr. Kathleen Moore, gynecologic oncologist and investigator with Sarah Cannon Research Institute, was recently featured on OncLive to discuss the evolving role of PARP inhibitors in ovarian cancer care. In the interview, Dr. Kathleen outlines how recent data and regulatory updates are shaping the use of PARP inhibitors in frontline and maintenance settings. She also highlights the importance of biomarker testing and individualized treatment strategies to optimize outcomes for patients. 📺 Watch the full interview: https://lnkd.in/eBER6KdJ #SCRI #OvarianCancer #PARPInhibitors #CancerResearch #GynecologicOncology #OncLive

September Spotlight: Tumor Markers   Accurate cancer diagnostics begins in the laboratory. This September, in recognition of ovarian and prostate cancer awareness, API is highlighting PT programs that strengthen confidence in oncology testing.   Through API’s Tumor Markers Program (#183) laboratories can assess key biomarkers widely used in cancer care, including: ➡️ CA-125 – supports early detection and monitoring of ovarian cancer ➡️ PSA – used for screening and monitoring treatment response in prostate cancer ➡️ CEA – helps diagnosis and monitoring recurrence of colorectal and other cancers   API provides fifteen samples over three shipments per year, allowing labs to maintain regulatory compliance by routinely assessing performance of their tumor marker assays. Your role in cancer diagnostics is vital— ensure confidence in your laboratory’s tumor marker testing with API.   Explore Program #183 and more in the API Catalog: https://api-pt.com/catalog #API #ProficiencyTesting #LaboratoryExcellence #CancerDiagnostics #LabTesting

🩸 Liquid Biopsies: Transforming Breast Cancer Care 🎗️ Fascinating insights from Dr. Pavani Chalasani (GW) on how liquid biopsies are revolutionizing breast cancer management! 🔬 Key Takeaways: 🔹 Early Detection of Resistance: ctDNA tests can identify ESR1 mutations before clinical progression, allowing therapy switches that significantly delay disease advancement (as shown in PADA-1 and SERENA-6 trials) 🔹 Beyond Tissue Limitations: When tissue biopsies are unsafe or unavailable, validated plasma assays provide actionable mutation data for PIK3CA, ESR1, and other targetable alterations 🔹 Complementary, Not Replacement: While tissue biopsy remains the gold standard for diagnosis, liquid biopsies excel at real-time monitoring and capturing tumor heterogeneity across lesions 🔹 Clinical Reality: FDA-cleared platforms like Guardant360 and FoundationOne Liquid CDx are widely used, though routine surveillance protocols and insurance coverage remain evolving challenges The future of precision oncology is here - using a simple blood draw to outsmart cancer's next move! 💪 What are your thoughts on integrating liquid biopsies into routine cancer care? #LiquidBiopsy #BreastCancer #PrecisionMedicine #Oncology #ctDNA #PersonalizedCare #CancerResearch #MedicalInnovation Source: https://lnkd.in/eFG687AZ

HER3-DXd is emerging as a potential new option for patients with HR+/HER2− breast cancer, a population that continues to face limited treatment choices after progression on endocrine therapy. In the ICARUS-BREAST01 trial, HER3-DXd demonstrated a 53.5% response rate. But how should we interpret these results compared with T-DXd in HER2-low or HER2-zero disease, and what does this mean for real-world practice? In this interview, Dr Barbara Pistilli, head of the Breast Cancer Unit at Gustave Roussy Éducation Cancer Center, walks through the trial data, why study design matters, and how emerging biomarkers such as ESR1 mutations, TP53 status, and tumor architecture could help identify patients most likely to benefit. She also touches on immune pathway activation, the potential for ADC–immunotherapy combinations, and the unanswered questions heading into phase III. Watch the full conversation here: 👉 https://lnkd.in/gPqX-sU7 Read the full study in Nature Portfolio Medicine: https://lnkd.in/gzHmQ8ek Paolo Tarantino Sarah Sammons MD Maria Fernanda Mosele Noémie Corcos Livia Pierotti Yoann Pradat Loïc Le Bescond

Fibronectin Fiber Tension: A New Mechanical Biomarker in Breast Cancer Progression In 2025, Dr. Arnaud Miéville and colleagues published a groundbreaking study in Advanced Science revealing how fibronectin fibers progressively lose their tension as breast cancer advances from ductal carcinoma in situ (DCIS) to invasive carcinoma. Using a peptide tension probe (FnBPA5), the study provides new insight into extracellular matrix (ECM) remodeling, a critical factor influencing cancer invasiveness. While healthy breast tissue and DCIS exhibit stretched fibronectin fibers, invasive tumors display relaxed, untensed fibers—closely associated with cancer cells, fibroblasts, and immune cells. This mechanical transformation could serve as a biophysical biomarker of tumor aggressiveness and a potential gateway for stroma-targeted therapies and immunotherapy strategies. For those interested in reading more, find the full study here: https://lnkd.in/dbxph6yX Special thanks to the research team for their valuable contribution to understanding the physical and biological interplay in breast cancer progression. #OncologyFrontier #BreastCancer #TumorMicroenvironment #ECM #CancerMechanobiology #Immunotherapy #AdvancedScience #CancerResearch

🚨 Breakthrough in Gynecologic Cancer Treatment 🚨 Ovarian cancer remains one of the deadliest gynecologic malignancies due to late-stage detection and aggressive tumor biology. Traditional treatments like carboplatin, paclitaxel, and doxorubicin have extended survival, but recurrence and resistance remain major challenges. 💡 Recently, the FDA granted Breakthrough Therapy Designation to Raludotatug Deruxtecan (R-DXd), targeting platinum-resistant ovarian, primary peritoneal, and fallopian tube cancers expressing CDH6. This offers hope for patients post-bevacizumab treatment. 🔬 Key insights from ovarian cancer research: Type I vs Type II tumors differ significantly in aggressiveness and molecular profile. BRCA1/2 mutations and TP53 alterations drive tumorigenesis and guide targeted therapies. Staging (I–IV) determines treatment strategy and prognosis. This milestone highlights the importance of precision oncology and molecular profiling in advancing treatment and improving survival outcomes. ✨ A new era of hope for women battling ovarian cancer. #Oncology #GynecologicCancer #OvarianCancer #FDA #BreakthroughTherapy #PrecisionMedicine #CancerResearch Image Source - OCRA

APOBEC3 Mutagenesis: A Key Driver of Therapy Resistance in Breast Cancer In 2024, Dr. Avantika Gupta, PhD and collaborators published a compelling preprint uncovering how APOBEC3 mutagenesis contributes to therapeutic resistance in breast cancer. Using a comprehensive dataset of 3,880 tumor-normal paired samples, the team found that APOBEC3-associated mutational signatures were significantly enriched in post-treatment hormone receptor–positive (HR+) tumors compared to treatment-naïve cancers. Importantly, this mutational process was independently linked to shorter progression-free survival in patients receiving antiestrogen plus CDK4/6 inhibitor therapy. Through whole-genome sequencing of clinical samples and breast cancer models, the study demonstrated that active APOBEC3 mutagenesis fosters endocrine and targeted therapy resistance, often through alterations such as RB1 loss-of-function mutations. Evidence of APOBEC3 activity in pre-treatment samples underscores its pervasive role in tumor evolution and highlights its potential as both a biomarker and a therapeutic target in overcoming resistance. Read the full preprint on PubMed:https://lnkd.in/dzgWM6mi Sincere thanks to Dr. Gupta and the research team for their valuable contribution to advancing our understanding of therapy resistance in breast cancer. #OncologyFrontier #BreastCancer #TranslationalResearch #TherapyResistance #APOBEC3 #PrecisionOncology #CDK46Inhibitors #EndocrineResistance #CancerGenomics

Corticosteroids are commonly used to manage lung cancer symptoms, yet they might be hindering the efficacy of certain immunotherapies, according to a new study led by Keck Medicine of USC researchers. In this Q&A, one of the researchers discusses implications of this study and how these findings might inform future treatment protocols or dosage guidelines for lung cancer patients. https://lnkd.in/gnuwfzbm

When radiation is used for cancer, it usually comes from outside—a carefully aimed beam that passes through skin and nearby tissue to reach the tumor. That approach helps many people, but it can still touch healthy areas. This clinical trial explores a different idea for colorectal cancer: tiny “guided lights” on the inside. ✅ First, there’s a special scan to look for a marker on tumor cells called GRPR (think of it like a recognizable doorbell). ✅ If your scan is GRPR-positive, the study drug LY4257496 is designed to travel through the bloodstream, find that doorbell, and deliver a very small dose of radiation right where it lands—sometimes together with capecitabine. Why it matters: For people with metastatic or unresectable colorectal cancer who’ve already tried standard treatments, this is not “more chemo.” It’s an attempt to make radiation smarter and more focused— from the inside, guided by what shows up on your scan. Early-phase means the goals are safety and finding the right dose first, but it extends a proven concept from other cancers into CRC. Trial ID: NCT07114601 Get Informed (and learn about other CRC trials): https://lnkd.in/gVem6qVN #mCRC #ColorectalCancer #ClinicalTrials #RadioligandTherapy #Theranostics

Not all mismatch repair profiles respond to treatment the same way. While MSI-H/dMMR tumors are often associated with frequent frameshift mutations and immunogenicity, proficient MMR (pMMR) or microsatellite stable (MSS) tumors—also called not MSI-H—present a different and distinct research profile. These tumors: 🧬 Maintain intact mismatch repair systems 🔬 Exhibit lower mutational loads and limited immunogenicity 📉 Show reduced sensitivity to immune checkpoint inhibitors alone Recent studies have highlighted the promise of combination approaches—pairing immune checkpoint inhibitors with targeted or anti-angiogenic therapies—opening new avenues to advance cancer research. Determining MMR status remains an important tool for advancing precision oncology. 🔗 Learn about the latest insights on MSS and pMMR colorectal and endometrial tumor research: https://bit.ly/4pXbnsz #MMR #MSS #pMMR #MSIH #OncologyResearch #CancerGenomics #ImmunoOncology